Advertisement
Australia markets close in 2 hours 22 minutes

  • ALL ORDS

    7,790.90
    -108.00 (-1.37%)
     

  • ASX 200

    7,541.30
    -100.80 (-1.32%)
     

  • AUD/USD

    0.6390
    -0.0035 (-0.55%)
     

  • OIL

    84.70
    +1.97 (+2.38%)
     

  • GOLD

    2,405.00
    +7.00 (+0.29%)
     

  • Bitcoin AUD

    96,590.95
    -466.81 (-0.48%)
     

  • CMC Crypto 200

    1,278.38
    +392.84 (+42.77%)
     

  • AUD/EUR

    0.6005
    -0.0026 (-0.43%)
     

  • AUD/NZD

    1.0872
    -0.0002 (-0.02%)
     

  • NZX 50

    11,738.86
    -97.18 (-0.82%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,167.99
    -217.88 (-1.33%)
     

  • NIKKEI 225

    37,055.38
    -1,024.32 (-2.69%)
     

Luminar's Deal With Mercedes a 'Major Commercial Win:' Northland

Investing.com
·1-min read

By Sam Boughedda

Investing.com — Luminar Technologies (NASDAQ:LAZR) deal with Mercedes-Benz was a "major commercial win," said Northland Capital Markets analyst Gus Richard.

Luminar is an autonomous vehicle sensor and software company. On Thursday, Luminar announced a partnership with Mercedes-Benz for its lidar technology to be used in Mercedes vehicles.

"Reference designs at NVDA, partnership with Mobileye (F:0ME), first production cars with Lidar in 2022 (Volvo XC90 and SAIC R Brand), and now Mercedes passenger car win it is difficult to dispute that LAZR is the Lidar Leader," Richard said.

ADVERTISEMENT

The analyst said further that they now "expect more design wins this year and these early platform wins lock in the company for a long time and provide a first-mover advantage."

While Luminar shares closed 11% higher Thursday on news of the deal, its stock price has given back most of those gains on Friday, currently down 8.4%.

Related Articles

Luminar's Deal With Mercedes a 'Major Commercial Win:' Northland

Intel to invest up to $100 billion in Ohio chip plants

GSK, Vir ramping up U.S. output of COVID antibody drug